A detailed history of Russell Investments Group, Ltd. transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Russell Investments Group, Ltd. holds 170,374 shares of AKBA stock, worth $311,784. This represents 0.0% of its overall portfolio holdings.

Number of Shares
170,374
Previous 175,802 3.09%
Holding current value
$311,784
Previous $179,000 25.14%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$0.94 - $1.55 $5,102 - $8,413
-5,428 Reduced 3.09%
170,374 $224,000
Q1 2024

May 08, 2024

SELL
$1.27 - $2.24 $7,948 - $14,020
-6,259 Reduced 3.44%
175,802 $321,000
Q4 2023

Feb 05, 2024

SELL
$0.8 - $1.28 $4,551 - $7,281
-5,689 Reduced 3.03%
182,061 $225,000
Q3 2023

Nov 13, 2023

SELL
$0.87 - $1.84 $929 - $1,965
-1,068 Reduced 0.57%
187,750 $214,000
Q1 2023

May 09, 2023

SELL
$0.56 - $1.15 $1,772 - $3,639
-3,165 Reduced 1.65%
188,818 $105,000
Q4 2022

Feb 08, 2023

SELL
$0.25 - $0.58 $983 - $2,280
-3,932 Reduced 2.01%
191,983 $111,000
Q3 2022

Nov 04, 2022

SELL
$0.3 - $0.46 $8,917 - $13,673
-29,725 Reduced 13.17%
195,915 $60,000
Q2 2022

Jul 29, 2022

SELL
$0.32 - $0.67 $9,704 - $20,319
-30,327 Reduced 11.85%
225,640 $78,000
Q1 2022

May 05, 2022

SELL
$0.72 - $2.93 $43,257 - $176,034
-60,080 Reduced 19.01%
255,967 $182,000
Q4 2021

Jan 21, 2022

SELL
$2.26 - $3.34 $204,830 - $302,714
-90,633 Reduced 22.29%
316,047 $713,000
Q3 2021

Nov 08, 2021

SELL
$2.35 - $3.88 $123,140 - $203,312
-52,400 Reduced 11.41%
406,680 $1.17 Million
Q2 2021

Aug 04, 2021

BUY
$2.83 - $4.2 $18,878 - $28,018
6,671 Added 1.47%
459,080 $1.74 Million
Q1 2021

May 10, 2021

BUY
$2.92 - $5.06 $25,170 - $43,617
8,620 Added 1.94%
452,409 $1.53 Million
Q4 2020

Feb 08, 2021

BUY
$2.22 - $3.78 $554,582 - $944,289
249,812 Added 128.78%
443,789 $1.24 Million
Q3 2020

Nov 09, 2020

SELL
$2.39 - $13.08 $176,647 - $966,755
-73,911 Reduced 27.59%
193,977 $484,000
Q2 2020

Aug 05, 2020

BUY
$6.67 - $13.58 $1.01 Million - $2.06 Million
151,768 Added 130.7%
267,888 $3.63 Million
Q1 2020

May 06, 2020

BUY
$4.1 - $10.24 $11,311 - $28,252
2,759 Added 2.43%
116,120 $880,000
Q4 2019

Jan 29, 2020

BUY
$3.16 - $6.73 $358,220 - $762,919
113,361 New
113,361 $716,000
Q2 2019

Aug 09, 2019

SELL
$4.1 - $8.05 $221,235 - $434,378
-53,960 Closed
0 $0
Q1 2019

May 13, 2019

BUY
$5.41 - $8.73 $8,807 - $14,212
1,628 Added 3.11%
53,960 $442,000
Q4 2018

Feb 11, 2019

BUY
$5.39 - $9.15 $118,041 - $200,385
21,900 Added 71.96%
52,332 $289,000
Q3 2018

Oct 26, 2018

BUY
$7.44 - $10.65 $51,038 - $73,059
6,860 Added 29.1%
30,432 $268,000
Q2 2018

Aug 08, 2018

SELL
$9.15 - $11.34 $207,128 - $256,703
-22,637 Reduced 48.99%
23,572 $236,000
Q1 2018

May 11, 2018

BUY
$9.53 - $15.68 $63,498 - $104,475
6,663 Added 16.85%
46,209 $440,000
Q4 2017

Feb 06, 2018

SELL
$14.24 - $19.59 $542,458 - $746,261
-38,094 Reduced 49.06%
39,546 $612,000
Q3 2017

Nov 07, 2017

BUY
$13.06 - $19.67 $1.01 Million - $1.53 Million
77,640
77,640 $1.53 Million

Others Institutions Holding AKBA

About Akebia Therapeutics, Inc.


  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $336M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track This Portfolio

Track Russell Investments Group, Ltd. Portfolio

Follow Russell Investments Group, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.